/ Active, not recruitingNot Applicable Digital Therapeutics (ET-101) Research on Efficiency and Safety About Mild Cognitive Impairment, Randomized, Sham Device, Assessor-blinded, Multi-center Pivotal Study
The purpose of this study is to evaluate the efficiency and safety of a digital therapeutics(ET-101) for mild cognitive impairment (MCI).
This is a randomized, sham-controlled, assessor-blinded, 24-week parallel study.
100 MCI patients will be randomly assigned to two groups. The control group will be provided with a sham device.
100 Clinical Results associated with Emocog Inc
0 Patents (Medical) associated with Emocog Inc
100 Deals associated with Emocog Inc
100 Translational Medicine associated with Emocog Inc